Royalty Pharma plc (RPRX) FY2024 Q3 P&L / Income Statement

Royalty Pharma plc (RPRX) FY2024 Q3 P&L / Income Statement

Income statement for 2024-07-01 through 2024-09-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total income and other revenues

564,690,000 US dollars

Total operating (income)/expense, net

negative 170,384,000 US dollars

Operating income

735,074,000 US dollars

Total other (income)/expense, net

71,284,000 US dollars

Consolidated net income before tax

806,358,000 US dollars

Income tax expense

0 US dollars

Consolidated net income

806,358,000 US dollars

Income from financial royalty assets

533,166,000 US dollars

Other royalty income and revenues

31,524,000 US dollars

Research and development funding expense

500,000 US dollars

Provision for changes in expected cash flows from financial royalty assets

negative 227,604,000 US dollars

General and administrative expenses

56,720,000 US dollars

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to Royalty Pharma plc: $543.99 M; to noncontrolling interests: $262.37 M.